Please assess the completion status of the following clinical trial:

Trial Title: Single-cell CBD Biomarkers of Inflammation Reduction in People Living With HIV

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Willingness to take CBD and to participate in follow up for two months~* Older than 21 and younger than 60~* Under antiretroviral therapy for 5+ years and suppressed viral load (CD4 count \<350cells/ml)~Exclusion Criteria:~* Conditions/medications that may impair the immune response, e.g., rheumatoid arthritis, cancer, diabetes, chronic infections, CAD (Cold agglutinin disease), cellulitis, autoimmune diseases such as lupus, sarcoidosis~* All medications that may affect inflammation such as aspirin, steroids, statins; CD4 count \<350cells/ml), pregnancy, and current marijuana or CBD use (urine drug screen)~* UF(University of Florida)/Shands staff and students will not be considered for enrollment

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- CBD Intervention (Type: EXPERIMENTAL): Participants will self-administer CBD daily for 2 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).